Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05869773 · ClinicalTrials.gov registry record · Phase 4
A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
A Phase 4 study of Narcolepsy, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT05869773: Completed Phase 4 study of Narcolepsy, sponsored by Jazz Pharmaceuticals.
NCT05869773 is a Phase 4 study of Narcolepsy that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 160 participants, below the 367-participant average among 12 other Narcolepsy trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05869773, a Phase 4 study of Narcolepsy, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
Conditions Studied
Interventions
- DRUG JZP258
Study Locations (20)
California
- Science 37 - Culver City
- M3 Wake Research - Encino
- So Cal Clinical Research - Huntington Beach
- Long Beach Research Institute - Lakewood
- Stanford School of Medicine - Redwood City
- TriValley Sleep Center - San Ramon
- SDS Clinical Trials, Inc. - Santa Ana
Florida
- FWD Clinical Research - Boca Raton
- Meris Clinical Research, LLC - Brandon
- Ocean Wellness Center - Miami
- Serenity Research Center LLC - Miami
- Florida Pediatric Research Institute, LLC - Orlando
Georgia
- Sleep Practitioners, LLC - Macon
Idaho
- Saltzer Medical Group - Nampa
Kentucky
- University of Louisville - Louisville
Maryland
- University of Maryland Medical Center - Baltimore
Massachusetts
- Neurocare, Inc - Newton
Michigan
- Sparrow Health System - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2025-03-10 |
| Phase | Phase 4 |
What the finished NCT05869773 record still lists
NCT05869773 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 367-participant average among 12 other Narcolepsy trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Narcolepsy appearing as the primary indexed condition, and to 1 intervention - of which JZP258 is the first listed.
NCT05869773 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05869773 about?
NCT05869773 is a clinical study titled "A Switch Study From High-Sodium Oxybate to XYWAV to Evaluate Changes in Blood Pressure in Participants With Narcolepsy". The aim of this study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new informatio...
What is the current status of trial NCT05869773?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 160 participants. The study started on 2023-06-26. Estimated completion is 2025-03-10.
What conditions does trial NCT05869773 study?
This clinical trial studies the following conditions: Narcolepsy.
What interventions are being tested in trial NCT05869773?
The interventions under investigation include: JZP258 (DRUG).
Who is sponsoring clinical trial NCT05869773?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05869773 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Narcolepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05869773's enrollment target sits among peer trials
160 6th of 12 higher than 7 of 12 other Narcolepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Narcolepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SUNOSI® (Solriamfetol) Pregnancy Registry
RECRUITING
-
A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1
RECRUITING · Phase 1
-
Child and Adolescent Registry for Participants With Narcolepsy
RECRUITING
-
WAKIX® (Pitolisant) Pregnancy Registry
RECRUITING
-
A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy
COMPLETED · Phase 2
-
Narcolepsy Nightmare Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI